WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007014762) GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/014762    International Application No.:    PCT/EP2006/007632
Publication Date: 08.02.2007 International Filing Date: 31.07.2006
IPC:
C07D 235/02 (2006.01), A61K 31/4166 (2006.01)
Applicants: GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB) (For All Designated States Except US).
DEAN, Anthony, William [GB/GB]; (GB) (For US Only).
PORTER, Roderick, Alan [GB/GB]; (GB) (For US Only)
Inventors: DEAN, Anthony, William; (GB).
PORTER, Roderick, Alan; (GB)
Agent: KONDO, Rie; GlaxoSmithKline, Corporate Intellectual Property, (CN925.1) 980 Great West Road, Brentford, Middlesex TW8 9GS (GB)
Priority Data:
0515903.3 02.08.2005 GB
0605410.0 16.03.2006 GB
Title (EN) GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
(FR) INHIBITEURS DE TRANSPORTEURS GLYT1 ET LEURS UTILISATIONS DANS LE TRAITEMENT DE TROUBLES NEUROLOGIQUES ET NEUROPSYCHIATRIQUES
Abstract: front page image
(EN)The invention provides a compound of formula (I) or a solvate thereof: (I) wherein R1, R2, R3, R4, R5, R6, and n are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.
(FR)L'invention concerne un composé représenté par la formule (I) ou un solvate de celui-ci et l'utilisation de ce composé. Dans la formule (I), R1, R2, R3, R4, R5, R6 et n sont tels que définis dans la spécification. Ledit composé inhibe les transporteurs GlyT1 et est utilisé pour traiter certains troubles neurologiques et neuropsychiatriques, notamment, la schizophrénie.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)